South Korea, June 30 -- Circio Holding ASA and NeoRegen Biotech, today jointly announce the signing of a second Material Transfer Agreement (MTA) to advance their ongoing collaboration for the delivery of circular RNA (circRNA) expression-based therapeutics. The collaboration now is progressing to the in vivo preclinical stage. This milestone follows the successful proof-of-concept (POC) results from in vitro studies conducted under their initial MTA, signed in 2023. The collaboration was formed to provide solutions to the critical challenges in the delivery of nucleic acid medicines.Circio is the world-leader in circular RNA-based expression systems for next generation gene and cell therapy. Its unique circVec expression platform has demon...